LEXINGTON, MA - February 20, 2004 - Synta Pharmaceuticals Corp. today announced that Safi Bahcall, Ph.D., President and Chief Executive Officer, will present at the BIO CEO & Investor Conference on Wednesday, February 25, 2004 at 2:00 PM EST in the Park Avenue Suite North of the Waldorf-Astoria in New York, NY. Dr. Bahcall will provide a corporate overview and an update on Synta's pipeline.
The presentation will be webcast and can be accessed from Synta's website at http://www.syntapharma.com/. A replay of the presentation will be archived there after the event.
Synta Pharmaceuticals is an emerging pharmaceutical company focused on discovering, developing, and commercializing breakthrough products for severe medical conditions. Synta has a diverse pipeline of small-molecule therapeutics for the treatment of cancer and immune disorders, with its two most advanced products in Phase II clinical development. Synta developed as a buyout of the U.S. subsidiary of a large Japanese pharmaceutical company. As a result, Synta has an experienced and successful drug discovery team that has worked together for over ten years. All clinical candidates were developed by this team using Synta's chemistry-driven drug discovery platform. Synta fully owns all rights for all of its products. For more information, please see http://www.syntapharma.com/.